NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- The Global Pharmacovigilance Market is expected to witness CAGR of 13.45% and is projected to reach USD9,300 million by 2024 from USD 3,800 million in 2017. The key factors propelling the growth of market includes increasing incidence of adverse drug reactions (ADRs) coupled with increase prevalence of acute and chronic disease, and rising consumption of drugs. Moreover, rising demand in end-use industry owing to new drug developments further impelling the market growth. However, lack of awareness among the healthcare providers may hinder the market growth.

Adverse Drugs Reactions (ADRs) Is Driving the Growth of the Industry

Pharmacovigilance science relates to detection, assessment, understanding, and prevention of adverse effects of drugs and drug-related problems. ADRs are major health problems in outpatient and inpatient clinical setting. It is an essential part of pharmacovigilance systems. Adverse drug reactions caused by nonimmune and immune mechanism are major cause of mortality and morbidity worldwide. Incidence and severity of ADRs vary by patient’s characteristics such as sex, age, genetic or geographic factors, and coexisting disorders; and drug factor including drug type, route of drug administration, bioavailability, and dosage.

Moreover, rate of hospitalization of patients is increasing due to the adverse effect of drugs. Pharmacovigilance plays an important role in the surveillance of ADRs. It is a tool to collect information of ADRs to establish the causal relationship between drugs and the adverse reactions. During the clinical trials of a new drug development, it is prominent to explore the dependability of drugs. Additionally, in recent years there have been a substantial growing number of clinical trials in the developed and developing countries. In their approval of clinical trials, the government looks at safety and efficacy of novel products under investigation.

Global Pharmacovigilance Market Regional Insight

Geographically, North America held the largest market share of the global market, owing to large production of new drugs development, along with increasing number of clinical trials has led to further need pharmacovigilance of drugs, resulting in higher demand in this region. Moreover, ADRs, contribute to more than 100,000 deaths in the United States annually and most top 10 leading causes of death. Regulator bodies are developing active surveillance approaches to assess the risk of medicine in the post-market phase of the novel products. The growth of pharmacovigilance market in Europe is also attributed to growing number of adverse drug reactions, and growing demand in end-use industry. Asia-Pacific is expected to be the fastest growing market, due to growing number of acute and chronic diseases burden and increasing drug safety concerns. Moreover, growing number of pharmaceutical and biotechnological companies, and increasing awareness about adverse drug reactions in this region.

Browse full research report with TOC on “Global Pharmacovigilance Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024” at:

To purchase report:

Key findings from the report:

  • On the basis of clinical trials, the phase IV trials segment held the share of the market in 2017
  • Based on the service, the contract outsourcing segment held the major share of the market in 2017, and expected to continue its dominance over the forecast period
  • Geographically, North America held major share of the market in 2017, owing to favorable government regulations, and presence of major key player in this region
  • Some of the key companies operating in the market include Laboratory Corporation of America Holdings, IBM Corporation, Capgemini, ICON plc, PAREXEL International Corporation, United BioSource Corporation, BioClinica, Wipro Ltd., Cognizant, Quintiles IMS Holdings, Inc., GlaxoSmithKline, Novartis International AG, and among others

This report segments global pharmacovigilance market by clinical trials, service, type of method, end-use industry, and region.

By Clinical Trials

  • Preclinical Studies
  • Phase I Trials
  • Phase II Trials
  • Phase III Trials
  • Phase IV Trials

By Service

  • Contract Outsourcing
  • In-house

By Type of Method

  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining
  • Intensified ADR Reporting
  • Spontaneous Reporting

By End-use Industry

  • Pharmaceutical
  • Medical Device
  • Biotechnological

By Region

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Middle East and Africa

About Energias Market Research Pvt. Ltd. -

Energias Market Research launched with the objective to provide in-depth market analysis, business research solutions, and consultation that is tailored to our client’s specific needs based on our impeccable research methodology.

With a wide range of expertise from various industrial sectors and more than 50 industries that include energy, chemical and materials, information communication technology, semiconductor industries, healthcare and daily consumer goods, etc. We strive to provide our clients with a one-stop solution for all research and consulting needs.

Our comprehensive industry-specific knowledge enables us in creating high quality global research outputs. This wide-range capability differentiates us from our competitors.


Mr. Alan Andrews

Business Development Manager

For any queries email us:

To purchase report:

Call us: +1-716-239-4915